Cantor Fitzgerald’s Novo Nordisk NVO Stock Holding History

Cantor Fitzgerald’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.79M	Sell	100,000 -100,000	-50%	-$4.3M	0.05%	134
2026 Q1	$7.35M	Sell	200,000 -400,000	-67%	-$19M	0.11%	93
2025 Q4	$30.5M	Sell	600,000 -100,000	-14%	-$5.11M	0.46%	53
2025 Q3	$38.8M	Buy	+700,000	New	+$41M	0.38%	51

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Cantor Fitzgerald's NVO Position: Q2 2026 in Review

Cantor Fitzgerald increased its Novo Nordisk (NVO) stake by 12% in Q2 2026, buying an estimated $1.31M and bringing the position to 292,094 shares worth $14M. The position accounts for 0.15% of the portfolio, ranked #81.

Cantor Fitzgerald first reported a position in NVO in Q4 2022 and has held it in 11 quarters since. The position peaked at $47.6M in Q3 2025. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Cantor Fitzgerald held 292,094 shares of Novo Nordisk worth $14M as of Q2 2026.
Cantor Fitzgerald bought 30,520 Novo Nordisk shares in Q2 2026, an estimated $1.31M.
Novo Nordisk made up 0.15% of Cantor Fitzgerald's portfolio in Q2 2026, its #81 holding.
Cantor Fitzgerald first reported a position in Novo Nordisk in Q4 2022 and has held it in 11 quarters since.
Cantor Fitzgerald's Novo Nordisk position peaked at $47.6M in Q3 2025.
1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cantor Fitzgerald's 13F filing for Q2 2026, filed 14 Aug 2026.